Table 2 Utilities and costs parameters input in model
From: Cost-effectiveness analysis of duodenal–jejunal bypass sleeve device for people with obesity
parameters | Base value (range) | distribution | Distribution parameters | source |
|---|---|---|---|---|
Health Utilities | ||||
 Class I obesity without comorbidities | 0.95 (0.85, 1) | Beta | α = 30; β = 2 | [69] |
 Class II obesity without comorbidities | 0.94 (0.84, 1) | Beta | α = 31; β = 2 | [69] |
 Diabetes (BMI ≥ 25 kg/m2) | 0.86 (0.69, 1) | Beta | α = 16; β = 3 | [70] |
 Remission diabetes | 0.95 (0.76, 1) | Beta | α = 26; β = 1 | [71] |
 Uncontrol diabetes | 0.77 (0.69, 0.84) | Beta | α = 92; β = 28 | [72] |
 FLD | 0.85 (84, 0.86) | Beta | α = 4162; β = 735 | [73] |
 CC | 0.76 (0.68, 0.83) | Beta | α = 94; β = 30 | [74] |
 DC | 0.63 (0.56, 0.69) | Beta | α = 133; β = 77 | [75] |
 HCC | 0.41 (0.36, 0.44) | Beta | α = 235; β = 343 | [75] |
 LT | 0.65 (0.52, 0.78) | Beta | α = 33; β = 18 | [76] |
 Post-LT | 0.71 (0.57, 0.85) | Beta | α = 28; β = 11 | [76] |
 remission-FLD | 0.85 (0.84, 0.86) | Beta | α = 16,652; β = 2939 | [73] |
 remission-CC | 0.85 (0.84, 0.86) | Beta | α = 16,652; β = 2939 | [73] |
 CHD | 0. 78 (0. 24, 1) | Beta | α = 32; β = 9 | [77] |
 MI | 0.65 (0.58, 0.71) | Beta | α = 134; β = 72 | [78] |
 Post-MI | 0.8 (0.72, 0.88) | Beta | α = 76; β = 19 | [79] |
 Stroke | 0.65 (0.73, 0.76) | Beta | α = 2524; β = 1359 | [80] |
 Post-stroke | 0.74 (0.66, 0.81) | Beta | α = 96; β = 34 | [80] |
 Utility decrements among class I obesity | 0.02 (0.01, 0.03) | Beta | α = 15; β = 737 | [81] |
 Utility decrements among class II obesity | 0.06 (0.03, 0.08) | Beta | α = 25; β = 427 | [81] |
Costs (CNY ¥) | ||||
Intervention costs | ||||
 DJBS placement and removal costs  (Excluded DJBS) | 2,007.20 (704.9, 5,242.51) | Gamma | α = 3; β = 668 | Supplementary Table 5 |
 DJBS device | 26,500.00 (25,500, 27,500) | Gamma | α = 2689; β = 10 | TONGEE Medical estimate |
Comorbidities related drug costs | 96.70 (44.92, 254.71) | Gamma | α = 3; β = 30 | Clinical trial |
Costs of adverse events | Â | Â | Â | Supplementary Table 6 |
 ILI group | 32.54 (27.44, 63.02) | Gamma | α = 13; β = 3 |  |
 DJBS group | 497.37 (378.00, 668.81) | Gamma | α = 8; β = 177 |  |
Follow-up monitoring costs | 46.05 (25.50, 113.00) | Gamma | α = 9; β = 46 | Supplementary Table 8 |
Disease state management costs | ||||
 T2DM | 5,914.27 (4,629.28, 6,9432.92) | Gamma | α = 96; β = 62 | [55] |
 Remission T2DM | 5,277.86 (4131.14, 6943.92) | Gamma | α = 96; β = 55 | [55] |
 Uncontrol T2DM | 6,277.48 (4,913.57,7,370.35) | Gamma | α = 96; β = 65 | [55] |
 CC | 21,876.57 (7,585.82, 35,222.79) | Gamma | α = 9; β = 2373 | [82] |
 DC | 48,723.56 (28,965.52, 66,377.95) | Gamma | α = 25; β = 1953 | [82] |
 HCC | 102,845.01 (72,364.59, 128,893.28) | Gamma | α = 49; β = 2112 | [82] |
 LT | 446,172.99 (315,422.36, 630,836.52) | Gamma | α = 29; β = 15,158 | [83] |
 Post-LT | 70,927.01 (63,081.19, 77,555.75) | Gamma | α = 353; β = 201 | [83] |
 FLD | 2,019.32 (1,580.58, 2,370.87) | Gamma | α = 96; β = 21 | [84] |
 CHD | 11,445.68 (8,958.87, 13,438.31) | Gamma | α = 96; β = 119 | [85] |
 MI | 51,179.98 (13,898.97, 180,640.08) | Gamma | α = 1; β = 36,929 | [86] |
 Post-MI | 825.36 (139.77, 1,389.90) | Gamma | α = 6; β = 129 | [86] |
 Stroke | 22,607.04 (16,806.20, 36,451.90) | Gamma | α = 19; β = 1161 | [87] |
 Post-stroke | 3,985.64 (3,430.32, 6,369.83) | Gamma | α = 27; β = 147 | [87] |